Abstract:Introduction: Sickle Cell Disease (SCD) is an inflammatory and vaso-occlusive pathology. Multiple lipid mediators: resolvins, protectins and maresins, collectively known as Specialized Pro-resolving Mediators (SPMs), that are biosynthesized from Omega-3-PolyUnsaturated Fatty Acids (O3PUFAs), docosahexaenoic acid and eicosapentaenoic acid, appear to play a role in the resolution of inflammation. In a recent study, we have documented the presence of SPMs including Resolvin-D1 (RvD1), 17R-RvD3, and their pathway markers in plasma from both children with SCD and age-and race-matched controls with a significant increase in RvD1 levels noted in plasma from children with SCD. In an SCD mouse model exposed to hypoxia/reoxygenation, a previous study has shown that oral administration of 17R-RvD1, the longer acting isomer of RvD1, promotes resolution of SCD-associated inflammation and tissue damage. Objectives: We assessed whether there were any associations in children with SCD between baseline plasma levels of RvD1 and either markers of inflammation, endothelial activation and hemolysis or SCD-related clinical correlates. Methods: Multiplex assays were employed to assess endothelial activation markers (soluble adhesion molecules VCAM-1, ICAM-1 and E-selectin), and inflammatory cytokines (IL-1β, IL-4, IL-6, IL-10, TNF-α and CRP) in plasma. A 3-year retrospective review of individual SCD patient records was performed, and the number of painful episodes of vaso-occlusion or VOC, including those complicated by the occurrence of acute chest syndrome (ACS) were recorded. Total cumulative painful episodes over a 3-year period were included in the analysis. Spearman Rank Correlation was employed to assess the association between two variables. Results: Consistent with the published results, levels of endothelial activation markers (soluble VCAM-1 and soluble E-selectin), cytokines (IL-4, IL-6 and TNF-α), CRP and LDH were increased in SCD plasma compared to controls (Table-1). No significant associations were found in SCD between RvD1 or other lipid mediators and markers of endothelial activation or inflammation (Table-2). However, there were two significant associations noted between 5-HEPE and IL-1β, and between 12-HETE and IL-6. Plasma levels of the hemolytic marker LDH positively correlated with PGE2, TxB2, 7-HDHA, 5-HEPE and 5-HETE (Table-2). Review of medical history revealed 33 of 45 subjects (73%) had at least one VOC episode, and 17 (38%) had at least one ACS episode in the past 3 years. Subjects who had at least one ACS episode in the past 3 years also reported at least one VOC episode during the same period. There was no statistically significant difference in the RvD1 level by VOC [median RvD1 (ng/ml) of 0.056 in VOC -ve sub-group (n=12) vs 0.084 in VOC +ve sub-group (n=33), p=0.748] or ACS history [median RvD1 (ng/ml) of 0.060 in ACS -ve sub-group (n=28) vs 0.104 in ACS +ve sub-group (n=17), p=0.256]. There was no statistically significant association between levels of RvD1 and the total number of VOC/ACS in the past 3 years (correlation coefficient = -0.06, p=0.694). Summary and Conclusions: Because of the documented pro-resolving and anti-inflammatory effects of orally administered 17R-RvD1 in a mouse model of SCD, and elevated basal plasma levels of RvD1 in children with SCD, we investigated whether endogenous RvD1 provides protection against inflammation and clinical complications in SCD children. Other lipid mediators, which were synthesized from O3PUFAs and arachidonic acid, present in increased levels in SCD plasma and potentially involved in modulation of inflammation were also included in the analysis. Unlike in SCD mouse model in which exogenous RvD1 exerted anti-inflammatory effect in ex-vivo experiments and orally administered 17R-RvD1 promoted resolution of inflammation and down-regulated adhesion molecule expression and cytokine production, endogenous RvD1 did not show any significant association with markers of inflammation and endothelial activation or clinical correlates in a small group of SCD children under healthy condition. No significant findings were noted with other lipid mediators. Whether these lipid mediators modulate inflammation during crisis, pre- or post-crisis clinical conditions and whether their production is different during these clinical conditions compared to steady state healthy condition require further investigation.

Associations Between Resolvin D1 and Culprit Plaque Morphologies: An Optical Coherence Tomography Study in Patients with ST-Segment Elevation Myocardial Infarction

The Role of Serum Resolvin D1 Levels in Determining the Presence and Prognosis of ST-Segment Elevation Myocardial Infarction

Serum resolvin D1 potentially predicts neurofunctional recovery, the risk of recurrence and death in patients with acute ischemic stroke

Prognostic significance of serum resolvin D1 levels in patients with acute supratentorial intracerebral hemorrhage: a prospective longitudinal cohort study

Residual inflammatory risk and vulnerable plaque in the carotid artery in patients with ischemic stroke

Prognostic Implications of Plaque Characteristics and Stenosis Severity in Patients with Coronary Artery Disease.

Relationship Between Hs-Crp, Prommp-1, TIMP-1 and Coronary Plaque Morphology: Intravascular Ultrasound Study

Prognostic Implications of Comprehensive Whole Vessel Plaque Quantification Using Coronary Computed Tomography Angiography

Regression of human coronary artery plaque is associated with a high ratio of (18-hydroxy-eicosapentaenoic acid + resolvin E1) to leukotriene B4

"Pro-Resolution" and Anti-Inflammation, A Role of Rve1 in Anti-Atherosclerosis and Plaque Stabilization

Correlation of sLOX-1 Levels and MR Characteristics of Culprit Plaques in Intracranial Arteries with Stroke Recurrence

Resolvin-D1 (RvD1) and Its Association with Markers of Inflammation, Endothelial Activation, Hemolysis and Clinical Correlates in Children with Sickle Cell Disease (SCD)

Association between Multiple Inflammatory Biomarkers and Remnant Cholesterol Levels in Patients with Percutaneous Coronary Intervention: A Large-Scale Real-World Study

In vivo predictors of plaque erosion in patients with ST-segment elevation myocardial infarction: a clinical, angiographical, and intravascular optical coherence tomography study

Pancoronary plaque characteristics in STEMI patients with rapid plaque progression: An optical coherence tomography study

106Plasma Trimethylamine N-oxide is Associated with Culprit Plaque Characterization As Assessed by Optical Coherence Tomography in Patients with Acute Myocardial Infarction

Association of Trimethylamine N-Oxide Levels and Calcification in Culprit Lesion Segments in Patients With ST-Segment–Elevation Myocardial Infarction Evaluated by Optical Coherence Tomography

The association between glucose-related variables and plaque morphology in patients with ST-segment elevated myocardial infarction

Association between apolipoprotein B/A1 ratio and coronary plaque vulnerability in patients with atherosclerotic cardiovascular disease: an intravascular optical coherence tomography study

Impact of Radial Wall Strain on Serial Changes in Vascular Physiology in Patients with Intermediate Coronary Stenosis

Discriminating Carotid Atherosclerotic Lesion Severity By Luminal Stenosis And Plaque Burden A Comparison Utilizing High-Resolution Magnetic Resonance Imaging At 3.0 Tesla